Who has been buying Kyungdong Pharmaceutical stock?

4 distinct insiders have filed 27 disclosed insider purchases in Kyungdong Pharmaceutical (011040), most recently on 2026-07-13. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Kyungdong Pharmaceutical have?

Kyungdong Pharmaceutical has 27 buy-side and 0 sell-side disclosures on record, covering ₩372M ($258K) in total reported value, spanning 2024-01-11 to 2026-07-13.

Where does StockDrifts get Kyungdong Pharmaceutical insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Kyungdong Pharmaceutical 011040

Company

경동제약Kyungdong Pharmaceutical

Insiders

Buys

Total Value

₩372M ($258K)

Avg Return

+1.60%

Last Filing

2026-07-13

Kyungdong Pharmaceutical (011040) has 27 disclosed insider purchases and 0 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩372M ($258K) in reported transaction value. The earliest filing StockDrifts holds for Kyungdong Pharmaceutical is dated 2024-01-11; the most recent is 2026-07-13. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +1.60%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-13	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	2.7K	₩4,900	+1.8%	₩13M ($9K)
2026-07-07	SELL	증여	류 기 성 Ryu Ki-seong	CEO	-300.0K	₩4,995	+0.1%	₩1.5B ($1.1M)
2026-06-09	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	400	-	-	-
2026-06-08	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	1.0K	-	-	-
2026-06-04	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	91	-	-	-
2026-02-26	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	1.0K	-	-	-
2026-01-26	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	900	₩5,760	+4.7%	₩5M ($4K)
2026-01-23	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	1.9K	₩5,670	+6.3%	₩11M ($8K)
2025-10-30	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	5.0K	₩5,720	+5.4%	₩29M ($20K)
2025-10-27	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	1.5K	₩5,820	+3.6%	₩9M ($6K)
2025-10-24	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	660	₩5,800	+4.0%	₩4M ($3K)
2025-09-08	BUY	자사주상여금	류 기 성 Ryu Ki-seong	CEO	50	-	-	-
2025-09-08	BUY	자사주상여금	류덕희 Ryu Deok-hee	Honorary Chairman	50	₩5,970	+1.0%	₩299K ($207)
2025-06-30	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	2.2K	₩5,960	+1.2%	₩13M ($9K)
2025-06-27	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	7.7K	₩5,990	+0.7%	₩46M ($32K)
2025-05-09	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	2.0K	₩5,790	+4.2%	₩12M ($8K)
2025-05-08	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	3.0K	₩5,830	+3.4%	₩17M ($12K)
2025-05-07	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	2.0K	₩5,820	+3.6%	₩12M ($8K)
2025-04-04	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	1.0K	₩5,530	+9.0%	₩6M ($4K)
2025-03-13	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	1.6K	₩5,690	+6.0%	₩9M ($6K)
2025-03-12	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	40	₩5,680	+6.2%	₩227K ($158)
2025-03-11	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	2.3K	₩5,670	+6.3%	₩13M ($9K)
2025-01-01	BUY	신규선임	이근호 Lee Geun-ho	moving	300	₩6,180	-2.4%	₩2M ($1K)
2024-12-12	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	501	₩6,030	+0.0%	₩3M ($2K)
2024-12-11	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	8.9K	₩5,940	+1.5%	₩53M ($37K)
2024-12-10	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	900	₩5,800	+4.0%	₩5M ($4K)
2024-11-14	BUY	Market Buy	김석범 Seokbeom Kim	moving	2.0K	₩5,990	+0.7%	₩12M ($8K)
2024-07-15	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	7.5K	₩6,840	-11.8%	₩51M ($36K)
2024-07-12	BUY	Market Buy	류덕희 Ryu Deok-hee	Honorary Chairman	2.3K	₩6,890	-12.5%	₩16M ($11K)
2024-05-08	BUY	Market Buy	김경훈 Kim Kyung-hoon	CEO	3.0K	₩6,350	-5.0%	₩19M ($13K)
2024-03-29	BUY	신규선임	박종식 Park Jong-sik	Outside Director	25.0K	₩6,490	-7.1%	₩162M ($113K)
2024-02-23	BUY	Market Buy	이경묵 Lee Kyung-mook	moving	2.2K	₩6,450	-6.5%	₩14M ($10K)
2024-01-11	BUY	자사주상여금	김석범 Seokbeom Kim	moving	500	₩6,660	-9.5%	₩3M ($2K)
2024-01-11	BUY	자사주상여금	이경묵 Lee Kyung-mook	moving	500	₩6,660	-9.5%	₩3M ($2K)

Frequently asked questions

Who has been buying Kyungdong Pharmaceutical stock?: 4 distinct insiders have filed 27 disclosed insider purchases in Kyungdong Pharmaceutical (011040), most recently on 2026-07-13. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Kyungdong Pharmaceutical have?: Kyungdong Pharmaceutical has 27 buy-side and 0 sell-side disclosures on record, covering ₩372M ($258K) in total reported value, spanning 2024-01-11 to 2026-07-13.
Where does StockDrifts get Kyungdong Pharmaceutical insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Kyungdong Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.